FAQ

EUK1001

 

Topic mentions per year

Topic mentions per year

2008-2017
0120082017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model.
Agonists of M1 muscarinic acetylcholine receptors are promising therapeutic agents for the treatment of Alzheimer's disease (AD… (More)
Is this relevant?
2012
2012
3-[3-(3-florophenyl-2-propyn-1-ylthio)-1, 2, 5-thiadiazol-4-yl]-1, 2, 5, 6-tetrahydro-1- methylpyridine oxalate, a novel xanomeline derivative, improves neural cells proliferation and survival in…
The present study analyzed the influence of 3-[3-(3-florophenyl-2-propyn-1-ylthio)-1, 2, 5-thiadiazol-4-yl]-1, 2, 5, 6-tetrahydro… (More)
Is this relevant?
2011
2011
Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline.
The M1/M4-preferring muscarinic agonist xanomeline was found to have some benefit in the treatment of the memory impairment of… (More)
Is this relevant?
2010
2010
A novel derivative of xanomeline improves fear cognition in aged mice.
The M1/M4 muscarinic acetylcholine receptor agonist xanomeline can significantly improve the cognitive function, but the… (More)
Is this relevant?
2008
2008
A novel derivative of xanomeline improved memory function in aged mice
To characterize the function of a new xanomeline-derived M1 agonist, 3-[3-(3-florophenyl-2-propyn-1-ylthio)-1,2,5-thiadiazol-4-yl… (More)
Is this relevant?